Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

This trial studies whether adding radioactive microspheres (yttrium-90, delivered directly into liver tumors) to standard chemotherapy improves outcomes for people with colorectal cancer that has spread to the liver and progressed after first-line treatment. **You may be eligible if...** - You are between 18 and 75 years old - Your colorectal cancer has spread to the liver (one lobe only) and your primary tumor has been removed - Your cancer progressed after first-line treatment - Your doctor has determined you are a candidate for the yttrium-90 microsphere procedure **You may NOT be eligible if...** - Your liver metastases involve both lobes - Your overall health does not support this combined treatment Talk to your doctor to see if this trial is right for you.